What Researchers Did
Chinese researchers compared 8 bone marrow transplant patients who received HBOT added to standard care for hemorrhagic cystitis (bladder bleeding) against 8 patients who received standard care alone.
What They Found
Patients who received HBOT had a significantly shorter duration of illness compared to the standard treatment group (p < 0.05). Pain scores dropped to below 2 on the numeric rating scale faster in the HBOT group. No significant adverse effects from HBOT were reported in any patient.
What This Means for Canadian Patients
For Canadians recovering from bone marrow or stem cell transplants, hemorrhagic cystitis can cause severe bladder pain, blood in urine, and prolonged hospitalization. This study adds to growing evidence that HBOT shortens the duration of this complication and reduces pain, without adding meaningful risk to already immunocompromised patients.
Canadian Relevance
Radiation cystitis is an OHIP-covered indication for HBOT in Ontario. Transplant-related hemorrhagic cystitis is biologically similar; coverage eligibility depends on the specific clinical circumstances.
Study Limitations
Only 16 patients total (8 per group) were included, making this one of the smallest comparative studies on this topic and limiting the statistical reliability of the findings.